



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

8-28-97

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

MEMORANDUM:

SUBJECT: **Coumaphos: Hazard Identification Report**

CASRN: 36-72-4
PC Code: 36501
Caswell: 355

FROM: John C. Redden., M.S. *[Signature]* 8/28/97
Risk Characterization and Analysis Branch
Health Effects Division (7509C)

THRU: Clark Swentzel, Chief Toxicology Branch II *[Signature]* 8/28/97
Chairman, Hazard Identification Committee
Health Effects Division (7509C)

TO: Dennis McNeilly
Reregistration Branch II
Special Review and Reregistration Division (7508W)

The HED Hazid Committee met on 8/21/97 to consider the Bayer proposal to conduct a one to two day dermal study for use in coumaphos risk assessment.

Bayer concurred that the 21-day dermal study was the proper endpoint (0.5 mg/kg/day based on cholinesterase inhibition) for the dip vat. However, for the animal spray use the exposure is of shorter duration.

Bayer supported this conclusion with a cattleman's Magazine survey, which indicated that the animal spray was applied to the whole herd in one day. The Registrant acknowledged that the survey had a low response rate. The Hazid Committee expressed concern that the exposure might be more than one day.

In addition, Bayer presented evidence that suggested that the NOEL for short term exposure would be significantly higher than the 21-day dermal study. The Committee



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

determined that the 5-day dermal range finding study was not appropriate for risk assessment, since a NOEL could not be established.

The Hazid Committee is recommending that the Registrant conduct a 5-7 day dermal study, with measure of plasma, RBC, and Brain Cholinesterase at appropriate intervals to characterize the time course of the effect. The Committee is recommending that this study be completed and submitted to the Agency in six months. In the interim the risk assessment will use the 21-day dermal endpoint.

The Committee is recommending that the Registrant submit the protocol to HED for review. Dr. William Sette volunteered to review the protocol


Individuals in Attendance

Hazard Identification Committee members present were David Anderson, William Burham (Chief, SAB, HED), Susan Makris, Melba Morrow, Nancy McCaroll, Kathleen Raffaele, John Redden, Jess Rowland, Clark Swentzel (Charirman, Hazard Identification Committee, HED).

Hazard Identification Committee members in absentia were Karl Baetcke (Senior Science Advisor, HED), and George Ghali (Executive Secretary, Hazard Identification Committee, HED).

Scientific reviewer(s) (Committee or non-committee member(s) responsible for data presentation; signature(s) indicate technical accuracy of panel report and concurrence with the hazard identification assessment review unless otherwise stated.

John Redden



cc:

Stephanie Irene
Pauline Wagner
Jess Rowland
Amal Mahfooz (OW)
Hazard ID File
Caswell File